NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

EGFR_IUO 3.20 Clinical Study Protocol

WithdrawnNA

Sponsor: Biocartis NV

Conditions: NSCLC

Interventions: Idylla EGFR_IUO/3.20 Mutation Test

An interventional, prospective clinical performance study protocol, for the testing of DNA extracted from FFPE Fine needle aspirate samples, using the Idylla EGFR\_IUO/3.20, from patients with Non-Small Cell Lung Cancer screened in AstraZeneca's NeoADAURA clinical trial (Protocol No. D516AC00001)

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

• All patients who provided consent (by signing and dating the Consent Form for AstraZeneca NeoADAURA Protocol No. D516AC00001), may be included in the device study.

Exclusion Criteria:

* Patients whose FFPE FNA samples are not Clinical Trial Assay evaluable will be excluded from the study.
* Patients with samples identified for the study which have insufficient testing material will also be excluded.